Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer
Mené sur 71 patients atteints d'un cancer de la prostate résistant à la castration et de stade métastatique, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse, et la toxicité d'un traitement combinant nivolumab et ipilimumab après l'échec d'au moins une ligne thérapeutique
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal state of prostate cancer with poor prognosis.1 Despite significant therapeutic advances, long-term disease control remains elusive for most patients. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for many solid tumors; however, prostate cancer has historically shown limited responsiveness to ICIs, likely because of a combination of low tumor mutational burden, low neoantigen load, and an immunologically cold tumor microenvironment.2-5 Consequently, attention has shifted toward identifying molecular and microenvironmental biomarkers that might enrich for patients likely to benefit from immunotherapy.
Journal of Clinical Oncology , éditorial, 2025